12,372 trials
Esophageal Squamous Cell Carcinoma (ESCC)
Primary: Progression-free Survival (PFS) — 29.0; 28.9 months — p=0.3016
Chagas Disease
Primary: Global PCR (Conventional PCR and Real-time Quantitative PCR) Immediately After the End of Treatment. — 16; 20 Participants
Esophageal Cancer
Primary: Independent Review Facility (IRF)-Assessed Progression-Free Survival (PFS) — 5.39; 6.18 months — p=<0.0001
Chronic Obstructive Pulmonary Disease
Primary: Untrimmed Airway Volume (siVaw) for Distal Region at Total Lung Capacity (TLC) - Actual Value for V2 Pre-dose and V3 Pre-dose — 1.4088; 1.3550 liters — p== 0.4521
Multiple Myeloma
Primary: Primary Analysis: Overall Minimal Residual Disease (MRD) Negative Rate — 35.4; 53.3 Percentage of participants — p==0.0004
Controlling Mild to Moderate Bleeding During Surgery
Primary: Absolute Time to Hemostasis — 4.00 Minutes
Friedreich Ataxia
Primary: Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set — 1.218; 2.828 units on a scale — p== 0.1440
Eosinophilic Esophagitis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 100; 167; 31; 298 Participants
Papillomavirus Infections
Primary: Stage I: Competitive Luminex Immunoassay (cLIA) Geometric Mean Titers (GMTs) for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age and…
Functional Dyspepsia
Primary: Change in the Overall Severity of Functional Dyspepsia Between Baseline and Week 8, as Measured by the LDQ Severity Score — -9.54; -9.17 units on a scale
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Primary: Hemagglutination Inhibition (HI) Antibody Titers Against H1N1, H3N2, B/Victoria, and B/Yamagata Influenza Vaccine Strains 29 Days After the Administration of High-Dose…
Type 2 Diabetes
Primary: Incident Type 2 Diabetes — 121; 109; 139; 115 Participants
Dry Eye Disease
Primary: Least Squares Mean Percentage Change From Baseline in Goblet Cell Density at Day 90 for 0.003% AR-15512 — 94.61 percent change — p=0.1765
Hypercholesterolemia
Primary: Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56 — -64.6; -6.3; -27.8; -36.5 Percent Change — p=<0.001
Generalized Myasthenia Gravis
Primary: Percentage of Effective Self-administrations (SA) of Zilucoplan (ZLP) Using the Zilucoplan-auto-injector (ZLP-AI) From Visit 1 to Visit 8 — 99.8 Percentage of ZLP-AI…